Holding IBD therapy for COVID-19 vaccine ‘does not impact’ infection, hospitalization risk

CHARLOTTE, N.C. — Withholding immunosuppressive therapy prior to or following COVID-19 vaccination did not impact the rate of breakthrough infection or hospitalizations in patients with inflammatory bowel disease, noted a presenter here.“Individuals on biologic and immunomodulating agents were excluded from clinical trials of the BNT162b2, or the Pfizer vaccine, and the mRNA-1273, or Moderna vaccine. However, the ACG strongly supports COVID-19 vaccination in this population,” Kiran K. Motwani, MD, internal medicine specialist at the University of Maryland Medical Center,Read More